ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,324.47
-0.42%
Dow Jones
44,705.53
-0.17%
Gold vs US Dollar
2,642.24
-0.02%
Brent Oil
73.92
0.43%
Bitcoin
96,543.93
0.60%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) News

IO Biotech (IOBT)

IO Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IOBT
DateTimeSourceHeadlineSymbolCompany
12/11/202421:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
12/11/202412:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
12/11/202412:05GlobeNewswire Inc.IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
11/11/202421:05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
07/11/202415:00GlobeNewswire Inc.IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNASDAQ:IOBTIO Biotech Inc
04/10/202413:00GlobeNewswire Inc.IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:IOBTIO Biotech Inc
14/09/202406:30GlobeNewswire Inc.IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerNASDAQ:IOBTIO Biotech Inc
30/08/202420:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
30/08/202420:05GlobeNewswire Inc.IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
26/08/202420:05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
13/08/202420:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
13/08/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
13/08/202411:05GlobeNewswire Inc.IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
25/07/202420:05GlobeNewswire Inc.IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024NASDAQ:IOBTIO Biotech Inc
11/06/202420:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
07/06/202420:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
07/06/202420:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
23/05/202412:30GlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
14/05/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
14/05/202412:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
14/05/202411:55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
24/04/202420:30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
15/04/202412:30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
09/04/202416:00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
05/04/202412:30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
11/03/202420:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
06/03/202421:11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
05/03/202422:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
05/03/202421:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
05/03/202421:40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:IOBT

Your Recent History

LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
SBTX
Skinbiotherapeutics
LSE
LGEN
Legal & General
LSE
SCLP
Scancell
LSE
THG
Thg
LSE
GGP
Greatland Gold
LSE
KEFI
Kefi Gold And Copper
LSE
MIN
Minoan
LSE
ENET
Ethernity Networks
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
ORCP
Oracle Power
LSE
EME
Empyrean Energy
LSE
IES
Invinity Energy Systems
LSE
GFM
Griffin Mining
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved